Page results
-
UCLH’s trial of the world’s first ‘gene silencing’ drug for Alzheimer’s disease has progressed into a larger and later stage trial, after promising early results.
-
Men currently attending a hospital outpatient clinic for prostate hormone injections every 3 or 6 months will be advised that (unless not clinically appropriate) their next injection will be administered at a local GP practice, usually by the practice nurse.
-
All semen analysis referrals should be made via the NHS e-Referral Service (e-RS). We will no longer be able to book semen analysis appointments through direct requests from patients or GP surgeries via email.
-
We are now administering new COVID-19 treatments for patients at highest risk in the community. The service can prescribe oral antivirals to be taken at home, and give intravenous antibody treatments at the hospital.
-
How we use your information at UCLH: what you need to know
-
This page is for patients who are about to start a course of radiotherapy to the pelvis for a gynaecological cancer.
-
A UCLH investment of £20 million will fund training for healthcare assistants and major new research facilities which will benefit patient care.
-
Information for new neuro-otology patients
-
People with obesity whose weight and health improve following drug treatment are likely to need the treatment long term, according to a UCLH and UCL study.
-
UCLH Director of Research Professor Bryan Williams has been elected as the next President of the International Society of Hypertension (ISH).
File results
-
FOI/2024/0162 - Various technology systems/ services used at Trust
-
FOI/2024/0163 - Renal cell carcinoma and melanoma treatments
-
FOI/2024/0166 - Recruitment systems/CRM platform
-
FOI/2024/0171 - Dermatology consultants
-
FOI/2024/0172 - Patients excluded from care at the Trust 2010-2023
-
FOI/2024/0179 - Water usage/ procurement
-
FOI/2024/0183 - Immunology Hidradenitis Suppurativa (HS) treatment
-
FOI/2024/0184 - IT spend/ Healthcare Information and Management Systems Society (HIMSS) EMRAM and INFRAM scores
-
FOI/2024/0190 - Scheduled appointments Did Not Attend (DNA) 2019-2023
-
FOI/2024/0192 - Net zero and decarbonisation targets